Skip to main content
. 2021 Oct 25;8:713658. doi: 10.3389/fcvm.2021.713658

Figure 3.

Figure 3

Current guideline directed approach (Class I indications 2021 ESC guidelines). HFrEF, Heart failure with reduced Ejection fraction; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; SGLT2, sodium-glucose cotransporter 2; AF, atrial fibrillation; LVEF, left ventricle ejection fraction; CRT, cardiac resynchronization therapy; MR, mitral regurgitation.